Get started

MERCK

MERCK GOOD OPPORTUNITY Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891 Entry on the bullish break of the dynamic trendine or on exceeding the weekly maximum. Excellent operation with a risk / return ratio of 1.20
NYSE:MRKLong
by UnknownUnicorn25541012
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs. " Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ." Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NYSE:BMY
by PennyStocks101
MRK - Merck & Co - WEEKLY Setup - Holding the 200emaI Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in any way, shape or form financial or trading advice. Good luck, happy trading and stay chill, 2degreez
NYSE:MRKLong
by UnknownUnicorn7216011
Targovax has the cheapest oncolytic virus on the marketONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated. Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice. Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
OSL:CRNALong
by savepiginvest
Disposable Surgical Robotic Device - BIG News Coming 8/17/20Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using the Company’s LIBERTY Robotic System. finance.yahoo.com On 1/13/20, H.C. Wainwright maintained a Buy rating on MBOT and raised the price target from $12 to $26.00. I think this device could be a game changer. Disposable medical devices is where the future is going especially for sanitary reasons. Watch this stock Monday, 8/17/2020, it could run hard. I think the stock has been consolidating for a while and is coiling and ready to explode higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:MBOTLong
by HotCharts
Merger Approved - Huge Drug Company & Dirt Cheap Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Today, news that the merger with Upjohn was approved hit the news wires. www.bizjournals.com Mylan is in my opinion, one of the cheapest drug stocks in the sector at current levels. The stock currently trades at only 4x projected 2020 and 2021 earnings. The stock should be upwards of $25 to $30 a share with the merger approval. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Up..Up..& Away! Priority Review for Cancer DrugAt 8:30 AM NEWS This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer. The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much. Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news. At 4:05 PM NEWS Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis. This company has a lot of positive things moving forward including... On 6/11/2020, the stock got a boost with a price target of $45.00 a share. Daily Chart looks good with indicators turning up, Bullish Weekly Chart also looks Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Bullish Charts - Oversold & Undervalued Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreement with Merck KGaA; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and collaboration with Valneva SE to develop and commercialize Valneva's Lyme disease vaccine candidate VLA15. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer is one of the most unappreciated stocks in its industry and the low price shows. Recently, institutions have taken notice and started upgrading the stock with price targets north of $40.00 a share. Pfizer is also working on a COVID-19 vaccine and could be months ahead of other companies. On the daily chart, the stock is sitting is sitting and bouncing off support around $33.00. It's ready for a move up any day. Long!
NYSE:PFELong
by HotCharts
Bullish Charts - Acacia Buys Stake in 19 CompaniesAcacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,570 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. Acacia Research Corporation was founded in 1993 and is headquartered in Irvine, California. On 6/5/2020, Acacia agreed to acquire a portfolio of Life Science Assets for $283 Million The transaction allows Acacia to purchase shares in up to 19 public and private life sciences companies. Lets see where this one goes now. Looks undervalued at current levels. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ACTGLong
by HotCharts
CVS PHARMACY IS FILLING SCRIPTS FOR PALFORZIA - STRONG BUYWe just checked pharmacies around the North East PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States. Its parent company ranks as the 7th largest U.S. corporation by FY2017 revenues in the Fortune 500. The parent company of CVS Pharmacy's leading competitor (Walgreens) ranked 19th for the same time period. The stupid brokerage firms that just downgraded the stock price today because of a "so called slow roll-out" have no clue what they're doing or saying anymore. All these analysts had to do is pickup the phone and call around like we did! They're lazy!!! ANyone on this board wondering how easy it is to find out, call a CVS Pharmacy and ask them if they can fill a script for PALFORZIA, they will tell you YES,,, it is in the database for them to order..!!! We are passing along our research to some major brokerage firms so they will get behind the stock and push it up Palforzia Peanut Allergy Drug is available at CVS Pharmacy and soon to be available at Walgreens and other pharmacies throughout the USA This stock could blast off any day folks! We do not buy drug stocks so we are sitting on the sidelines just passing along solid and reliable information Factual information for this board is always a good thing to post especially since you don't get it from dumb analysts! DISCLAIMER This website and our posts are for general information only. No information, forward looking statements, or estimations presented herein represent any final determination on investment performance. While the information presented in this website and our posts has been researched and is thought to be reasonable and accurate, any investment is speculative in nature. StockKid, and/or our agents cannot and do not guarantee any rate of return or investment timeline based on the information presented herein. By reading and reviewing the information contained in this website and our posts, the user acknowledges and agrees that StockKid, and/or our agents do not assume and hereby disclaim any liability to any party for any loss or damage caused by the use of the information contained herein, or errors or omissions in the information contained in this website or our posts, to make any investment decision, whether such errors or omissions result from negligence, accident or any other cause. Investors are required to conduct their own investigations, analysis, due diligence, draw their own conclusions, and make their own decisions. Any areas concerning taxes or specific legal or technical questions should be referred to lawyers, accountants, consultants, brokers, or other professionals licensed, qualified or authorized to render such advice. In no event shall StockKid, and/or our agents be liable to any party for any direct, indirect, special, incidental, or consequential damages of any kind whatsoever arising out of the use of this website, our posts or any information contained herein. StockKid, and/or our agents specifically disclaim any guarantees, including, but not limited to, stated or implied potential profits, rates of return, or investment timelines discussed or referred to herein.
ALong
by UnknownUnicorn3159981
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor.
NYSE:MRKLong
by Investing_Fellow
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best! We took a long position at $82.00 several weeks ago. We feel the stock is worth at minimum, $150.00 all day long. KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales. Holding for the almost 3% Dividend and for the stock price appreciation into the future. 250,000 LONG @ $82.00 Best of Luck Everyone!
NYSE:MRKLong
by UnknownUnicorn3159981
Merck & Co. - MRK - SHORTKeep it Simple! Looking at MRK on the Daily there has been an easy setup for a short entry at the 87 range (Orange box). The frequent wicks into this range suggest that there are being fills made for short positions. I have set three profit targets (Green boxes) for this trade, where I will almost completely out of the trade by the third profit target. The trade made very good risk to reward. This trade is not too late for you to enter the short position, with a stop above the top of the range.
NYSE:MRKShort
by djhodnett